AlvotechALVO
Recorded

Alvotech UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration31 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Ash VermaAnalyst

All right. Good day, everybody. Welcome to UBS Biopharma Conference in London. Next company with me here, Alvotech. My name is Ash Verma. I cover specialty biotech and spec pharma, and we have Róbert and Balaji from Alvotech. Guys, thank you so much for joining us today.

Robert WessmanExecutive Chairman

Yeah, thank you, Ash. Pleasure.

Ash VermaAnalyst

Yeah, so a lot of exciting things going on with Alvotech. Maybe, I think most people are kind of familiar with the story, but if you can just kind of remind, what's the pure play biosimilar and- Yeah talk about some of the programs.

Robert WessmanExecutive Chairman

Yeah, exactly. I founded the company 2013. We knew that biologic would be the future of pharmaceutical, if you will. Those medications, as we all know, are quite effective, but very expensive. We predicted that there would be a very strong need for a company like ours post 2020. The concept was always pure play biosimilar, having end-to-end R&D, end-to-end manufacturing from vial fill to finished product, both drug substance, fill-finish, sterile. Then we do even assembly of our auto-injector. Then we have built out the commercial network now with 20 different partners, including Teva in U.S. and Advanz and STADA in Europe.

Robert WessmanExecutive Chairman

We have invested now over $2 billion into building the infrastructure, and we are super proud because we believe that we have one of the largest pipeline, in-house developed pipeline in the industry, and the company is clearly at a big inflection point today.

Ash VermaAnalyst

Right. Awesome. Maybe just, I guess there's a lot of focus on the base business, I'll start there, and then the exciting pipeline program coming for you. If you can kind of remind us, like the third quarter, how the business performance was, like there was STELARA, where is HUMIRA in terms of the opportunity?

Robert WessmanExecutive Chairman

Yeah. We did have a pretty decent quarter, third quarter. We delivered $31 million EBITDA and north of $110 million top line for the quarter. We are expecting absolutely record quarter in the fourth quarter. A lot of what we have been doing since middle of the year is basically been stockpiling for the fourth quarter, which will be, again, exceptionally month of December, for instance. If you look at what is on the market now, biosimilar to HUMIRA is doing very well in U.S. We have Teva as our partner, which is, of course, excellent partner, knows how to convert brands to biosimilars. They understand all the channel. Our product today is having second-best market share in the market.

Robert WessmanExecutive Chairman

We are seeing, of course, more conversion from HUMIRA to biosimilars, and I believe end of second quarter, that conversion was like a bit north of 60% and continues. We believe that Teva will continue to gain share. We launched into Europe into a bit more mature market because we decided to go for the high dose. The low dose already had launched the market two years earlier. Still, STADA, our business partner there, is doing quite well. We are, of course, with biosimilar to STELARA in U.S., again with Teva, doing well. We launched biosimilar to SIMPONI into Europe, among others, Lotus, Hulio, EYLEA, XGEVA. There, our marketing partner, Advanz, has already gained like 25% market share since we launched, and we are the only one on the market.

Robert WessmanExecutive Chairman

Overall, the base business as such is growing and will be growing into 2027.

Ash VermaAnalyst

Yeah. I guess one of the things that you started talking about maybe more this year is around diversifying the supply chain.

Ash VermaAnalyst

Yeah. Right? You have talked about Lotte and Fujifilm.

Ash VermaAnalyst

Yeah along with the Iceland facility that you have.

Ash VermaAnalyst

When you think about the pipeline build-out from here, when do these suppliers start to come in? Have you identified each program, and how does this sort of work across the three different sources that you have?

Robert WessmanExecutive Chairman

Yeah. Yeah. So, we invested in Iceland in our facility north of $500 million already. So, the hub and the base is in Iceland. What we are seeing now is we have around 30 products in our pipeline, and we believe this is one of the broadest pipeline in the industry, which is in-house developed. None of our products are in-licensed or developed by someone else. It is all in-house. We are then at this inflection point where we are imminently going to launch three new products into U.S. We are gaining market share on market products. We are gaining market share with our, a strong share with our biosimilar to SIMPONI in Europe. We decided to broaden our supply chain, if you will.

Robert WessmanExecutive Chairman

We chose two companies which are based in U.S., so best-in-class access to the U.S. market and the quality having bigger manufacturing tanks than we have. We are doing 2,000 liter. We can scale up to 6,000 liter with those companies. We wanted to diversify a bit because we are getting so many launches and so many opportunities. We have filed a biosimilar to ENTYVIO, first to file there, and we have filed the high-dose EYLEA, and should be getting approvals next year. We wanted to make sure long term we had a very efficient supply chain with the option of lower, smaller batches up to 6,000 liter to make sure that in bigger volumes, we will be highly competitive to anyone in the market. We will be getting drug substance out of those two partners late next year.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day